FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of veterinary internal medicine2019; 33(2); 933-941; doi: 10.1111/jvim.15425

Coding sequences of sarcoplasmic reticulum calcium ATPase regulatory peptides and expression of calcium regulatory genes in recurrent exertional rhabdomyolysis.

Abstract: Sarcolipin (SLN), myoregulin (MRLN), and dwarf open reading frame (DWORF) are transmembrane regulators of the sarcoplasmic reticulum calcium transporting ATPase (SERCA) that we hypothesized played a role in recurrent exertional rhabdomyolysis (RER). Objective: Compare coding sequences of SLN, MRLN, DWORF across species and between RER and control horses. Compare expression of muscle Ca2+ regulatory genes between RER and control horses. Methods: Twenty Thoroughbreds (TB), 5 Standardbreds (STD), 6 Quarter Horses (QH) with RER and 39 breed-matched controls. Methods: Sanger sequencing of SERCA regulatory genes with comparison of amino acid (AA) sequences among control, RER horses, human, mouse, and rabbit reference genomes. In RER and control gluteal muscle, quantitative real-time polymerase chain reaction of SERCA regulatory peptides, the calcium release channel (RYR1), and its accessory proteins calsequestrin (CASQ1), and calstabin (FKBP1A). Results: The SLN gene was the highest expressed horse SERCA regulatory gene with a uniquely truncated AA sequence (29 versus 31) versus other species. Coding sequences of SLN, MRLN, and DWORF were identical in RER and control horses. A sex-by-phenotype effect occurred with lower CASQ1 expression in RER males versus control males (P < .001) and RER females (P = .05) and higher FKBP1A (P = .01) expression in RER males versus control males. Conclusions: The SLN gene encodes a uniquely truncated peptide in the horse versus other species. Variants in the coding sequence of SLN, MLRN, or DWORF were not associated with RER. Males with RER have differential gene expression that could reflect adaptations to stabilize RYR1.
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2019-02-05 PubMed ID: 30720217PubMed Central: PMC6430904DOI: 10.1111/jvim.15425Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study investigates the role of three transmembrane regulators, Sarcolipin (SLN), myoregulin (MRLN), and dwarf open reading frame (DWORF), in recurrent exertional rhabdomyolysis (RER). It concludes that while the coding sequences of these specific peptides are not related to RER, different gene expressions could contribute to RER developments in males.

Objective, Hypothesis, and Methodology

  • This research attempted to understand if the transmembrane regulators of sarcoplasmic reticulum calcium transporting ATPase (SERCA) – Sarcolipin (SLN), myoregulin (MRLN), and dwarf open reading frame (DWORF) – play a significant role in recurrent exertional rhabdomyolysis (RER).
  • The team speculated that these regulators may have an impact on the development of RER, a muscle disease affecting horses.
  • The proteins SLN, MRLN, and DWORF were compared across different species and between RER-affected and healthy horses.
  • The study included a diverse set of horses: Twenty Thoroughbreds, 5 Standardbreds, and 6 Quarter Horses with RER, alongside 39 breed-matched controls.
  • Using Sanger sequencing, the researchers examined the SERCA regulatory genes and compared the amino acid sequences among not only the test and control group of horses but also human, mouse, and rabbit reference genomes.

Results

  • The results showed that SLN was the highest expressed horse SERCA regulatory gene, and it encoded a uniquely truncated peptide sequence in horses compared to other species.
  • The coding sequences of SLN, MRLN, and DWORF were found to be identical in both RER-infected and control horses.
  • However, a sex-by-phenotype effect was observed. Males with RER showed lower expression of calsequestrin (CASQ1) gene as compared to male controls and RER affected females.
  • Females, on the other hand, showed higher expression of calstabin (FKBP1A).

Conclusion

  • On concluding the study, the researchers found that in horses, the SLN gene, a regulatory gene for muscle calcium regulation, encodes a uniquely truncated peptide compared to other species.
  • The coding sequences of SLN, MRLN, or DWORF displayed no linkage with RER, contradicting the initial hypothesis held by the team.
  • Males with RER, however, showed differing gene expressions which could potentially be adaptations to stabilize the RYR1, a calcium release channel.

The results thus suggest further research in understanding the genetic adaptations could provide additional insight on managing recurrent exertional rhabdomyolysis in horses.

Cite This Article

APA
Valberg SJ, Soave K, Williams ZJ, Perumbakkam S, Schott M, Finno CJ, Petersen JL, Fenger C, Autry JM, Thomas DD. (2019). Coding sequences of sarcoplasmic reticulum calcium ATPase regulatory peptides and expression of calcium regulatory genes in recurrent exertional rhabdomyolysis. J Vet Intern Med, 33(2), 933-941. https://doi.org/10.1111/jvim.15425

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 33
Issue: 2
Pages: 933-941

Researcher Affiliations

Valberg, Stephanie J
  • McPhail Equine Performance Center, Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan.
Soave, Kaitlin
  • McPhail Equine Performance Center, Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan.
Williams, Zoë J
  • McPhail Equine Performance Center, Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan.
Perumbakkam, Sudeep
  • McPhail Equine Performance Center, Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan.
Schott, Melissa
  • McPhail Equine Performance Center, Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan.
Finno, Carrie J
  • Department of Population Health and Reproduction, University of California-Davis, Davis, California.
Petersen, Jessica L
  • Department of Animal Science, University of Nebraska-Lincoln, Lincoln, Nebraska.
Fenger, Clara
  • Equine Integrated Medicine, PLC, Lexington, Kentucky.
Autry, Joseph M
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota.
Thomas, David D
  • Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota.

MeSH Terms

  • Amino Acid Sequence
  • Animals
  • Case-Control Studies
  • Female
  • Gene Expression
  • Horse Diseases / genetics
  • Horses
  • Humans
  • Male
  • Mice
  • Muscle Proteins / genetics
  • Muscle Proteins / metabolism
  • Muscle, Skeletal
  • Rabbits
  • Rhabdomyolysis / genetics
  • Rhabdomyolysis / veterinary
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases / genetics

Grant Funding

  • D16Eq004 / Morris Animal Foundation
  • Grayson Jockey Club Research Foundation
  • R37 AG026160 / NIA NIH HHS
  • R01 AR032961 / NIAMS NIH HHS
  • R01 AG026160 / NIA NIH HHS
  • R01 HL129814, R37 AG26160 / DDT NIH
  • R01HL129814, R37AG26160 / Foundation for the National Institutes of Health
  • R01 HL129814 / NHLBI NIH HHS

Conflict of Interest Statement

Dr. Valberg is 1 of the owners of the patent for the PSSM genetic test and receives sales income from its use. Her financial interest has been reviewed and managed by the University in accordance with its conflict of interest policies.

References

This article includes 57 references
  1. Valberg S. Muscling in on the cause of tying up. In: Proceedings of the American Association of Equine Pracitioners, Anaheim, CA, 2012;85‐123.
  2. Isgren CM, Upjohn MM, Fernandez‐Fuente M. Epidemiology of exertional rhabdomyolysis susceptibility in standardbred horses reveals associated risk factors and underlying enhanced performance. PLoS One 2010;5:e11594.
    pmc: PMC2904368pubmed: 20644724
  3. MacLeay JM, Sorum SA, Valberg SJ, Marsh WE, Sorum MD. Epidemiologic analysis of factors influencing exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 1999;60:1562‐1566.
    pubmed: 10622169
  4. McGowan CM, Fordham T, Christley RM. Incidence and risk factors for exertional rhabdomyolysis in thoroughbred racehorses in the United Kingdom. Vet Rec 2002;151:623‐626.
    pubmed: 12479297
  5. Lentz LR, Valberg SJ, Balog EM, Mickelson JR, Gallant EM. Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 1999;60:992‐999.
    pubmed: 10451211
  6. Beech J, Lindborg S, Fletcher JE, Lizzo F, Tripolitis L, Braund K. Caffeine contractures, twitch characteristics and the threshold for Ca(2+)‐induced Ca2+ release in skeletal muscle from horses with chronic intermittent rhabdomyolysis. Res Vet Sci 1993;54:110‐117.
    pubmed: 8434138
  7. Lentz LR, Valberg SJ, Herold LV, Onan GW, Mickelson JR, Gallant EM. Myoplasmic calcium regulation in myotubes from horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2002;63:1724‐1731.
    pubmed: 12492289
  8. Ward TL, Valberg SJ, Gallant EM, Mickelson JR. Calcium regulation by skeletal muscle membranes of horses with recurrent exertional rhabdomyolysis. Am J Vet Res 2000;61:242‐247.
    pubmed: 10714513
  9. Dranchak PK, Valberg SJ, Onan GW. Exclusion of linkage of the RYR1, CACNA1S, and ATP2A1 genes to recurrent exertional rhabdomyolysis in Thoroughbreds. Am J Vet Res 2006;67:1395‐1400.
    pubmed: 16881852
  10. Movsesian MA, Nishikawa M, Adelstein RS. Phosphorylation of phospholamban by calcium‐activated, phospholipid‐dependent protein kinase. Stimulation of cardiac sarcoplasmic reticulum calcium uptake. J Biol Chem 1984;259:8029‐8032.
    pubmed: 6234308
  11. Vangheluwe P, Schuermans M, Zador E. Sarcolipin and phospholamban mRNA and protein expression in cardiac and skeletal muscle of different species. Biochem J 2005;389:151‐159.
    pmc: PMC1184547pubmed: 15801907
  12. MacLennan DH. Isolation of proteins of the sarcoplasmic reticulum. Methods Enzymol 1974;32:291‐302.
    pubmed: 4280487
  13. Shaikh SA, Sahoo SK, Periasamy M. Phospholamban and sarcolipin: Are they functionally redundant or distinct regulators of the sarco(endo)plasmic reticulum calcium ATPase?. J Mol Cell Cardiol 2016;91:81‐91.
    pmc: PMC4843517pubmed: 26743715
  14. Autry JM, Thomas DD, Espinoza‐Fonseca LM. Sarcolipin promotes uncoupling of the SERCA Ca(2+) pump by inducing a structural rearrangement in the energy‐transduction domain. Biochemistry 2016;55:6083‐6086.
    pmc: PMC5506494pubmed: 27731980
  15. Nelson BR, Makarewich CA, Anderson DM. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science 2016;351:271‐275.
    pmc: PMC4892890pubmed: 26816378
  16. Anderson DM, Makarewich CA, Anderson KM. Widespread control of calcium signaling by a family of SERCA‐inhibiting micropeptides. Sci Signal 2016;9:ra119.
    pmc: PMC5696797pubmed: 27923914
  17. McCue ME, Valberg SJ, Miller MB. Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis. Genomics 2008;91:458‐466.
    pmc: PMC2430182pubmed: 18358695
  18. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 2007;35:W71‐W74.
    pmc: PMC1933133pubmed: 17485472
  19. Touchberry CD, Wacker MJ, Richmond SR, Whitman SA, Godard MP. Age‐related changes in relative expression of real‐time PCR housekeeping genes in human skeletal muscle. J Biomol Tech 2006;17:157‐162.
    pmc: PMC2291775pubmed: 16741243
  20. Lindholm A, Piehl K. Fibre composition, enzyme activity and concentrations of metabolites and electrolytes in muscles of standardbred horses. Acta Vet Scand 1974;15:287‐309.
    pmc: PMC8407315pubmed: 4137664
  21. Ken Cumming WJ, Fulthorpe J, Hudgson P, Mahon M. Color Atlas of Muscle Pathology. London, UK: Mosby‐Wolfe; 1994.
  22. Finno CJ, Bordbari MH, Valberg SJ. Transcriptome profiling of equine vitamin E deficient neuroaxonal dystrophy identifies upregulation of liver X receptor target genes. Free Radic Biol Med 2016;101:261‐271.
    pmc: PMC5154892pubmed: 27751910
  23. Simmerman HK, Kobayashi YM, Autry JM. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled‐coil pore structure. J Biol Chem 1996;271:5941‐5946.
    pubmed: 8621468
  24. Wawrzynow A, Theibert JL, Murphy C, Jona I, Martonosi A, Collins JH. Sarcolipin, the “proteolipid” of skeletal muscle sarcoplasmic reticulum, is a unique, amphipathic, 31‐residue peptide. Arch Biochem Biophys 1992;298:620‐623.
    pubmed: 1416990
  25. Nakagawa T, Yokoe S, Asahi M. Phospholamban degradation is induced by phosphorylation‐mediated ubiquitination and inhibited by interaction with cardiac type Sarco(endo)plasmic reticulum Ca(2+)‐ATPase. Biochem Biophys Res Commun 2016;472:523‐530.
    pubmed: 26966065
  26. Colyer J. Phosphorylation states of phospholamban. Ann N Y Acad Sci 1998;853:79‐91.
    pubmed: 10603938
  27. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem 1986;261:13333‐13341.
    pubmed: 3759968
  28. Wegener AD, Simmerman HK, Lindemann JP, Jones LR. Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta‐adrenergic stimulation. J Biol Chem 1989;264:11468‐11474.
    pubmed: 2544595
  29. Ruse CI, Tan FL, Kinter M, Bond M. Intregrated analysis of the human cardiac transcriptome, proteome and phosphoproteome. Proteomics 2004;4:1505‐1516.
    pubmed: 15188417
  30. Zhou T, Li J, Zhao P. Palmitoyl acyltransferase Aph2 in cardiac function and the development of cardiomyopathy. Proc Natl Acad Sci U S A 2015;112:15666‐15671.
    pmc: PMC4697436pubmed: 26644582
  31. Froehlich JP, Mahaney JE, Keceli G. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry 2008;47:13150‐13152.
    pubmed: 19053265
  32. Montigny C, Decottignies P, Le Marechal P. S‐palmitoylation and s‐oleoylation of rabbit and pig sarcolipin. J Biol Chem 2014;289:33850‐33861.
    pmc: PMC4256321pubmed: 25301946
  33. Sahoo SK, Shaikh SA, Sopariwala DH. The N terminus of sarcolipin plays an important role in uncoupling sarco‐endoplasmic reticulum Ca2+‐ATPase (SERCA) ATP hydrolysis from Ca2+ transport. J Biol Chem 2015;290:14057‐14067.
    pmc: PMC4447977pubmed: 25882845
  34. Shanmugam M, Li D, Gao S. Cardiac specific expression of threonine 5 to alanine mutant sarcolipin results in structural remodeling and diastolic dysfunction. PLoS One 2015;10:e0115822.
    pmc: PMC4324845pubmed: 25671318
  35. Traaseth NJ, Ha KN, Verardi R. Structural and dynamic basis of phospholamban and sarcolipin inhibition of Ca(2+)‐ATPase. Biochemistry 2008;47:3‐13.
    pmc: PMC2699759pubmed: 18081313
  36. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle Nerve 2006;33:715‐731.
    pubmed: 16477617
  37. Ablorh NA, Thomas DD. Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy. Biophys Rev 2015;7:63‐76.
    pmc: PMC4356992pubmed: 28509982
  38. Magny EG, Pueyo JI, Pearl FM. Conserved regulation of cardiac calcium uptake by peptides encoded in small open reading frames. Science 2013;341:1116‐1120.
    pubmed: 23970561
  39. Asahi M, Sugita Y, Kurzydlowski K. Sarcolipin regulates sarco(endo)plasmic reticulum Ca2+‐ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban. Proc Natl Acad Sci U S A 2003;100:5040‐5045.
    pmc: PMC154294pubmed: 12692302
  40. Hughes E, Clayton JC, Kitmitto A, Esmann M, Middleton DA. Solid‐state NMR and functional measurements indicate that the conserved tyrosine residues of sarcolipin are involved directly in the inhibition of SERCA1. J Biol Chem 2007;282:26603‐26613.
    pubmed: 17616528
  41. Bhupathy P, Babu GJ, Periasamy M. Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca2+ ATPase. J Mol Cell Cardiol 2007;42:903‐911.
    pmc: PMC2743185pubmed: 17442337
  42. Gramolini AO, Kislinger T, Asahi M, Li W, Emili A, MacLennan DH. Sarcolipin retention in the endoplasmic reticulum depends on its C‐terminal RSYQY sequence and its interaction with sarco(endo)plasmic Ca(2+)‐ATPases. Proc Natl Acad Sci U S A 2004;101:16807‐16812.
    pmc: PMC534750pubmed: 15556994
  43. Maclennan DH. Interactions of the calcium ATPase with phospholamban and sarcolipin: structure, physiology and pathophysiology. J Muscle Res Cell Motil 2004;25:600‐601.
    pubmed: 16118852
  44. Oakenfull EA, Clegg JB. Phylogenetic relationships within the genus Equus and the evolution of alpha and theta globin genes. J Mol Evol 1998;47:772‐783.
    pubmed: 9847419
  45. Pant M, Bal NC, Periasamy M. Sarcolipin: A Key Thermogenic and metabolic regulator in skeletal muscle. Trends Endocrinol Metab 2016;27:881‐892.
    pmc: PMC5424604pubmed: 27637585
  46. Cheng AJ, Andersson DC, Lanner JT. Can't live with or without it: calcium and its role in Duchenne muscular dystrophy‐induced muscle weakness. Focus on “SERCA1 overexpression minimizes skeletal muscle damage in dystrophic mouse models”. Am J Physiol Cell Physiol 2015;308:C697‐C698.
    pubmed: 25740154
  47. Fritz KL, McCue ME, Valberg SJ. Genetic mapping of recurrent exertional rhabdomyolysis in a population of North American Thoroughbreds. Anim Genet 2012;43:730‐738.
    pmc: PMC3665002pubmed: 22497487
  48. Tozaki T, Hirota K, Sugita S. A genome‐wide scan for tying‐up syndrome in Japanese Thoroughbreds. Anim Genet 2010;41(Suppl 2):80‐86.
    pubmed: 21070280
  49. Norton EM, Mickelson JR, Binns MM. Heritability of recurrent exertional rhabdomyolysis in standardbred and thoroughbred racehorses derived from SNP genotyping data. J Hered 2016;107:537‐543.
    pmc: PMC5006745pubmed: 27489252
  50. Barrey E, Jayr L, Mucher E. Transcriptome analysis of muscle in horses suffering from recurrent exertional rhabdomyolysis revealed energetic pathway alterations and disruption in the cytosolic calcium regulation. Anim Genet 2012;43:271‐281.
    pubmed: 22486498
  51. Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Prog Biophys Mol Biol 2004;85:33‐69.
    pubmed: 15050380
  52. Dainese M, Quarta M, Lyfenko AD. Anesthetic‐ and heat‐induced sudden death in calsequestrin‐1‐knockout mice. FASEB J 2009;23:1710‐1720.
    pmc: PMC2698659pubmed: 19237502
  53. Beard NA, Dulhunty AF. C‐terminal residues of skeletal muscle calsequestrin are essential for calcium binding and for skeletal ryanodine receptor inhibition. Skelet Muscle 2015;5:6.
    pmc: PMC4389316pubmed: 25861445
  54. Vasu VT, Ott S, Hobson B. Sarcolipin and ubiquitin carboxy‐terminal hydrolase 1 mRNAs are over‐expressed in skeletal muscles of alpha‐tocopherol deficient mice. Free Radic Res 2009;43:106‐116.
    pmc: PMC2770087pubmed: 19204867
  55. Campanaro S, Romualdi C, Fanin M. Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet 2002;11:3283‐3298.
    pubmed: 12471055
  56. Liu N, Bezprozvannaya S, Shelton JM. Mice lacking microRNA 133a develop dynamin 2‐dependent centronuclear myopathy. J Clin Invest 2011;121:3258‐3268.
    pmc: PMC3148737pubmed: 21737882
  57. Schneider JS, Shanmugam M, Gonzalez JP. Increased sarcolipin expression and decreased sarco(endo)plasmic reticulum Ca2+ uptake in skeletal muscles of mouse models of Duchenne muscular dystrophy. J Muscle Res Cell Motil 2013;34:349‐356.
    pubmed: 23748997

Citations

This article has been cited 6 times.
  1. Li Y, Zhu X, Feng P, Qiu C, Xue X, Sun X. Simple molecules make difference: short peptides play a novel role in slowing senescence. NPJ Aging 2025 Nov 26;11(1):104.
    doi: 10.1038/s41514-025-00292-3pubmed: 41298538google scholar: lookup
  2. Valberg SJ, Velez-Irizarry D, Williams ZJ, Henry ML, Iglewski H, Herrick K, Fenger C. Enriched Pathways of Calcium Regulation, Cellular/Oxidative Stress, Inflammation, and Cell Proliferation Characterize Gluteal Muscle of Standardbred Horses between Episodes of Recurrent Exertional Rhabdomyolysis. Genes (Basel) 2022 Oct 14;13(10).
    doi: 10.3390/genes13101853pubmed: 36292738google scholar: lookup
  3. Autry JM, Svensson B, Carlson SF, Chen Z, Cornea RL, Thomas DD, Valberg SJ. Sarcoplasmic Reticulum from Horse Gluteal Muscle Is Poised for Enhanced Calcium Transport. Vet Sci 2021 Nov 23;8(12).
    doi: 10.3390/vetsci8120289pubmed: 34941816google scholar: lookup
  4. Autry JM, Karim CB, Perumbakkam S, Finno CJ, McKenzie EC, Thomas DD, Valberg SJ. Sarcolipin Exhibits Abundant RNA Transcription and Minimal Protein Expression in Horse Gluteal Muscle. Vet Sci 2020 Nov 13;7(4).
    doi: 10.3390/vetsci7040178pubmed: 33202832google scholar: lookup
  5. Autry JM, Karim CB, Cocco M, Carlson SF, Thomas DD, Valberg SJ. Purification of sarcoplasmic reticulum vesicles from horse gluteal muscle. Anal Biochem 2020 Dec 1;610:113965.
    doi: 10.1016/j.ab.2020.113965pubmed: 32956693google scholar: lookup
  6. Williams ZJ, Velez-Irizarry D, Petersen JL, Ochala J, Finno CJ, Valberg SJ. Candidate gene expression and coding sequence variants in Warmblood horses with myofibrillar myopathy. Equine Vet J 2021 Mar;53(2):306-315.
    doi: 10.1111/evj.13286pubmed: 32453872google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.